24 October 2023 :Aker BioMarine ASA today announces that it has acquired all krill related patents, pre-clinical and clinical data, and processing equipment from Nasdaq listedAcasti Pharma Inc. The transaction is a settlement towards a contractual obligation ofUSD 3.1 million Acasti has towardsAker BioMarine , and has no cash effects. With this transactionAker BioMarine continues to consolidate all relevant krill intellectual properties (IP), and further strengthen its leadership position. The data acquired, which documents the strong cardiovascular benefits from krill oil, will further strengthen the attractiveness of Superba® krill oil in the dietary supplement market. In addition, this givesAker BioMarine an option to later pursue pharmaceutical opportunities originated fromAcasti Pharma Inc. The company currently has no plans of pursuing that option. For further information, please contactChristopher Robin Vinter , VP IR & Corporate Finance Mobile: +47 911 60 820 Email: Christopher.vinter@akerbiomarine.com AboutAker BioMarine Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters ofAntarctica .Aker BioMarine is listed onOslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.
Click here for more information
© Oslo Bors ASA, source